🔬 China's Pioneering Role in Base Editing for Beta-Thalassemia Treatment
In a landmark achievement that underscores China's rising dominance in gene editing research, scientists from leading Chinese universities and biotech firms have reported the world's first clinical success using base editing to treat transfusion-dependent beta-thalassemia (TDT β-thalassemia). Published in the prestigious journal Nature on April 8, 2026, the phase 1 trial results demonstrate a transformative therapy called CS-101, developed by CorrectSequence Therapeutics (Correctseq) in collaboration with ShanghaiTech University and the First Affiliated Hospital of Guangxi Medical University. This one-time treatment has enabled five patients to achieve sustained transfusion independence, marking a potential cure for a debilitating genetic disorder that affects millions in southern China and Southeast Asia.
Base editing, a precise form of CRISPR-Cas9 technology, allows scientists to change a single DNA base pair without causing double-strand breaks, minimizing risks like unwanted mutations or chromosomal rearrangements associated with traditional gene cutting methods. By targeting the BCL11A gene's binding sites in the promoters of the HBG1 and HBG2 genes, the therapy reactivates fetal hemoglobin (HbF) production, compensating for defective adult beta-globin and restoring normal red blood cell function.
Understanding Beta-Thalassemia: A Major Public Health Challenge in China
Beta-thalassemia is an inherited blood disorder caused by mutations in the HBB gene, which encodes the beta-globin subunit of hemoglobin—the oxygen-carrying protein in red blood cells. In severe cases like TDT β-thalassemia, patients produce insufficient functional hemoglobin, leading to chronic anemia, ineffective erythropoiesis (red blood cell production), and dependence on lifelong blood transfusions every 2-5 weeks. Complications include iron overload from repeated transfusions, organ damage, infections, and high healthcare costs estimated at tens of thousands of yuan annually per patient.
In China, β-thalassemia carriers number around 30 million, with prevalence highest in southern provinces. Guangxi Zhuang Autonomous Region reports carrier rates exceeding 20-25%, making it one of the global hotspots alongside Hainan and Guangdong. Nationwide, the carrier rate for β-thalassemia is 2.21%, contributing to approximately 300,000 patients with severe forms. Premarital screening programs in high-prevalence areas have reduced severe births, but existing patients face lifelong burdens, highlighting the urgency for curative therapies developed by Chinese institutions.
The Evolution of Gene Editing: From CRISPR to Transformer Base Editing
Gene editing has revolutionized treatment for monogenic diseases like β-thalassemia. Traditional CRISPR-Cas9 cuts DNA to insert or delete sequences but risks off-target effects and indels (insertions/deletions). Base editing, pioneered in 2016, uses a catalytically dead Cas9 fused to a base-modifying enzyme (e.g., cytidine or adenine deaminase) to convert C·G to T·A or A·T to G·C precisely.
Chinese researchers at ShanghaiTech University's School of Life Science and Technology, led by teams including Jia Chen and Lijie Wang, advanced this with the transformer base editor (tBE) in 2021 (published in Nature Cell Biology). tBE incorporates a cleavable deoxycytidine deaminase inhibitor (dCDI) domain, enabling transient activation for high-efficiency editing (up to 80%) with near-zero off-target mutations. This innovation, incubated into Correctseq, powers CS-101.
- Step 1: Collect patient's CD34+ hematopoietic stem/progenitor cells (HSPCs) from peripheral blood after mobilization.
- Step 2: Ex vivo electroporation with tBE ribonucleoprotein targeting BCL11A motifs in HBG promoters.
- Step 3: Myeloablative conditioning (busulfan) to clear patient's bone marrow.
- Step 4: Infuse edited autologous HSPCs (CS-101), which engraft and produce HbF-rich red cells.
This process, scalable to clinical GMP standards, takes weeks and avoids donor matching issues of allogeneic transplants.
The Phase 1 Clinical Trial: Design and Patient Cohort
Conducted under NCT06024876, the open-label, single-arm phase 1 trial enrolled five adult patients (aged 18-35) with TDT β-thalassemia at the First Affiliated Hospital of Guangxi Medical University in Nanning. Patients had diverse HBB genotypes common in China, such as CD41/42 and IVS-II-654 mutations, requiring >100 mL/kg/year transfusions.
Each received 5-10 × 10^6 cells/kg CS-101 after busulfan conditioning. Manufacturing yielded 12 batches with >70% editing efficiency, high viability, and no genotoxicity. Median follow-up: 23 months (range 15-28 months).
Photo by Road Ahead on Unsplash
Remarkable Efficacy Results: Transfusion Independence Achieved
All five patients achieved rapid engraftment—median 16 days for neutrophils (>0.5 × 10^9/L) and 25 days for platelets (>20 × 10^9/L). Critically, every patient became transfusion-independent, with median time to last transfusion of 18 days post-infusion.
Total hemoglobin stabilized at 12.4 ± 1.0 g/dL by month 3, rising to ~13.4 g/dL by month 15. HbF levels reached 11.5 ± 0.9 g/dL (92% of total Hb), pancellular distribution in >90% erythrocytes. Bone marrow analysis confirmed edited HSPCs dominance and γ-globin upregulation. These outcomes surpass some CRISPR therapies like Casgevy, with faster HbF induction and higher stability.
| Patient | Follow-up (months) | Total Hb (g/dL, M3) | HbF (g/dL, M3) | Transfusion-Free (days to last) |
|---|---|---|---|---|
| 1 | 28 | 13.2 | 12.1 | 15 |
| 2 | 24 | 12.1 | 11.0 | 20 |
| 3 | 23 | 12.8 | 11.8 | 16 |
| 4 | 20 | 12.0 | 11.2 | 18 |
| 5 | 15 | 12.9 | 11.6 | 22 |
Safety Profile: Minimal Risks with Proven Stability
Safety was exemplary, with adverse events (AEs) primarily grade 3-4 cytopenias from conditioning, resolving without sequelae. No deaths, malignancies, or graft failure occurred. Off-target editing was negligible (<0.1% at 145 sites), confirmed by whole-genome sequencing. No R-loop persistence or chromosomal abnormalities detected, validating tBE's precision over nickase-based editors.
Long-term monitoring (up to 28 months) showed stable editing without clonal dominance, positioning CS-101 as safer than lentiviral therapies risking insertional mutagenesis.
Key Chinese Institutions Driving the Innovation
This success stems from synergistic university-industry collaboration:
- ShanghaiTech University: Invented tBE (Wang Lab, 2021); incubated Correctseq; provided editing platform and preclinical validation.
- First Affiliated Hospital of Guangxi Medical University: Led clinical trial; NHC Key Lab for Thalassemia Medicine; expertise in high-prevalence region.
- Fudan University Children's Hospital: Contributed HSPC expertise and molecular analysis.
Lead author Prof. Yongrong Lai (Guangxi Med U) hailed it as "homegrown technology at world-class level." These institutions exemplify China's higher education push in biotech, supported by national funds like NSFC.
Broader Implications for Chinese Patients and Healthcare
In Guangxi alone, >20% carrier rate translates to thousands of TDT cases straining resources. CS-101 offers a domestic, cost-effective cure (~1/3 of imported therapies), reducing transfusion costs (¥100,000+/year/patient) and complications. Early results in sickle cell disease (another CS-101 indication) expand scope. For Chinese higher ed, it boosts ShanghaiTech's global ranking in biotech, attracting talent and funding.
Trial details on ClinicalTrials.gov confirm ongoing expansion.
Photo by Zhu Edward on Unsplash
Challenges Overcome and Lessons for Future Trials
Challenges included scaling tBE to GMP (12 batches successful), ensuring HSPC viability post-editing, and managing conditioning toxicity. Solutions: optimized electroporation, cryopreservation, and real-time off-target monitoring. Compared to Casgevy (BCL11A CRISPR, approved 2023), CS-101 shows faster response and cleaner profile.
Future Outlook: Toward Global Approval and Expanded Access
Phase 2/3 trials (NCT06328764 for β-thal, others for SCD) launch soon, targeting 100+ patients. Correctseq's pipeline includes CS-121 (APOC3 for hyperlipidemia). Regulatory nods in China position it for NMPA approval by 2028, with international potential. Chinese universities continue leading, fostering spinouts and training next-gen researchers.
This breakthrough not only cures TDT β-thalassemia but elevates China's higher education as a biotech powerhouse, promising healthier futures for millions.